Evidence map›Paper›PMID 35449354›Full record

ArticleCell biology and toxicology2023

Deubiquitinase USP19 enhances phenylalanine hydroxylase protein stability and its enzymatic activity.

Neha Sarodaya, Apoorvi Tyagi, Hyun-Jin Kim, Jencia Carminha Colaco, Ju-Seop Kang, Woo Jin Kim, Kye-Seong Kim, Suresh Ramakrishna

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biology and toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Neha Sarodaya *Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, South Korea.
Apoorvi Tyagi *Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, South Korea.
Hyun-Jin KimDepartment of Pharmacology, College of Medicine, Hanyang University, Seoul, South Korea.
Jencia Carminha ColacoGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul, South Korea.
Ju-Seop KangDepartment of Pharmacology, College of Medicine, Hanyang University, Seoul, South Korea.
Woo Jin KimDepartment of Internal Medicine and Environmental Health Center, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, South Korea.
Kye-Seong KimGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul, South Korea. ks66kim@hanyang.ac.kr.
Suresh RamakrishnaGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul, South Korea. suri28@hanyang.ac.kr.ORCID 0000-0002-4038-1085
Hanyang University · KRKangwon National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phenylalanine hydroxylase (PAH) is the key enzyme in phenylalanine metabolism, deficiency of which is associated with the most common metabolic phenotype of phenylketonuria (PKU) and hyperphenylalaninemia (HPA). A bulk of PKU disease-associated missense mutations in the PAH gene have been studied, and the consequence of each PAH variant vary immensely. Prior research established that PKU-associated variants possess defects in protein folding with reduced cellular stability leading to rapid degradation. However, recent evidence revealed that PAH tetramers exist as a mixture of resting state and activated state whose transition depends upon the phenylalanine concentration and certain PAH variants that fail to modulate the structural equilibrium are associated with PKU disease. Collectively, these findings framed our understanding of the complex genotype-phenotype correlation in PKU. In the current study, we substantiate a link between PAH protein stability and its degradation by the ubiquitin-mediated proteasomal degradation system. Here, we provide an evidence that PAH protein undergoes ubiquitination and proteasomal degradation, which can be reversed by deubiquitinating enzymes (DUBs). We identified USP19 as a novel DUB that regulates PAH protein stability. We found that ectopic expression of USP19 increased PAH protein level, whereas depletion of USP19 promoted PAH protein degradation. Our study indicates that USP19 interacts with PAH and prevents polyubiquitination of PAH subsequently extending the half-life of PAH protein. Finally, the increase in the level of PAH protein by the deubiquitinating activity of USP19 resulted in enhanced metabolic function of PAH. In summary, our study identifies the role of USP19 in regulating PAH protein stability and promotes its metabolic activity. Graphical highlights 1. E3 ligase Cdh1 promotes PAH protein degradation leading to insufficient cellular amount of PAH causing PKU. 2. A balance between E3 ligase and DUB is important to regulate the proteostasis of PAH. 3. USP19 deubiquitinates and stabilizes PAH further protecting it from rapid degradation. 4. USP19 increases the enzymatic activity of PAH, thus maintaining normal Phe levels.

Indexed as

Phenylalanine HydroxylasePhenylketonuriasDeubiquitinating EnzymesEndopeptidasesHumansPhenylalanineProtein StabilityUbiquitin-Protein LigasesDeubiquitinating EnzymesEndopeptidasesPhenylalaninePhenylalanine HydroxylaseUbiquitin-Protein LigasesUSP19 protein, humanHomeostasisHyperphenylalaninemiaMetabolic activityProteolysisTetrahydrobiopterinUbiquitin proteasome system

Identifiers

PMID35449354
OpenAlexW4224250809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.